Navigation Links
LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
Date:2/25/2008

TORRANCE Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies, and it may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the Feb. 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Rowan T. Chlebowski, M.D., Ph.D., a lead investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), was the lead author of the report. He and his colleagues studied 16,608 post-menopausal women who participated in the Womens Health Initiative (WHI) clinical trial, a 15-year study that began in 1993.

The research team examined the effect of combined hormone therapy on breast cancer detection over five years and found it resulted in more than one in 10 women having otherwise avoidable mammogram abnormalities and one in 25 women having breast biopsies. Combined hormone therapy also compromised the diagnostic performance of mammograms and breast biopsies.

These findings represent a concern for post-menopausal women who are considering hormone therapy, said Dr. Chlebowski. They should take the results of this study into consideration and consult with their physicians before undergoing even short-term hormone therapy.

The study examined the use of conjugated equine estrogens plus medroxyprogesterone acetate for approximately five years. A total of 8,506 women were randomly assigned to receive a combination of estrogen (0.625 milligrams of conjugated equine estrogens per day) plus progesterone (2.5 milligrams of medroxyprogesterone acetate per day), while 8,102 took a placebo. Each woman received a mammogram and breast examination yearly, with biopsies performed based on physicians clinical judgment.

During the 5.6 years of the study, 199 women in the combined hormone group and 150 women in the placebo group developed breast cancer. Mammograms with abnormal results were more common among women taking hormones than among women taking placebos: 35 percent vs. 23 percent.

Women taking hormones had a 4 percent greater risk of having a mammogram with abnormalities after one year and an 11 percent greater risk after five years.

Breast biopsies also were more common among women taking combined hormone therapy than among those taking placebos: 10 percent vs. 6.1 percent.

After discontinuation of combined hormone therapy, the adverse effects on mammogram and breast biopsy performance were seen even in younger women in the fifth decade of life, so the finding may impact women just entering menopause as well, said Dr. Chlebowski.

The study found the adverse effect of combined hormone therapy on mammograms modulated but remained significantly different from that of placebo for at least 12 months, according to the studys authors.


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
2. Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science
3. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
4. Lung Cancer Alliance Urges Inclusion of $5 Billion for Biomedical Research in Economic Stimulus Package
5. BioMed Central bolsters radiology image collection
6. New nanotube findings by Stanford researchers give boost to potential biomedical applications
7. American Red Cross Announces New Leader for Biomedical Services
8. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
9. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
10. LA BioMed researchers find few emergency rooms fully equipped for pediatric patients
11. LA BioMed research finds simpler way to assess breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... With ProGlass Prism users now have the ability to simulate prism ... position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor ... Prism users are given the tools and effects to generate a fractal prismatic ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that he ... of the Management Committee when IFN was originally formed in 2002 where he was ... development of the business plan. He became the first paid employee of IFN ...
(Date:2/24/2017)... ... 24, 2017 , ... Castle Farms, the celebrated Northern ... with the winning couple announced on Feb. 14, 2017, on Facebook. The free ... vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in ... the month of February, patients who visit Hamlin Dental Group will receive a ticket ... two at the Cheesecake Factory. , Tickets are available for routine dental visits ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Urinary Incontinence Drugs Price ... in the global Urinary Incontinence market. The research answers the ... drugs marketed for Urinary Incontinence and their clinical attributes? How are ...
(Date:2/23/2017)... Research and Markets has announced the addition ... - 2016" report to their offering. ... The latest research Autism Spectrum Disorder ... and benchmarks in the global Autism Spectrum Disorder market. The ... are the key drugs marketed for Autism Spectrum Disorder and their ...
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG ... für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des ... ultraviolette Strahlung im Bereich zwischen 200 und 280 nm und ... von Bakterien, indem es ihre DNA zerstört. Das Produkt ... ...
Breaking Medicine Technology: